NextCure, Inc. (NXTC)
D
Pipeline Grade
Financial Position (from SEC Filings)
$15.2M
Cash & Equivalents
$13.4M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$7M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase1 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04699123 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | PHASE2 | Active Not Recruiting | 159 |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Meta... | PHASE2 | Active Not Recruiting | 97 |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Panc... | PHASE2 | Recruiting | 20 |
| NCT06792552 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | PHASE1 | Recruiting | 414 |
| NCT06774963 | A Phase 1 Study of LNCB74 in Advanced Solid Tumors | PHASE1 | Recruiting | 145 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-01 | 8-K | NextCure, Inc. (NXTC) (CIK 0001661059) - EX-99.3 | EDGAR |